Mirati Therapeutics, Inc. (NASDAQ:MRTX) has been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.10.
A number of analysts recently commented on the stock. Jefferies Group LLC reissued a “hold” rating and set a $5.50 price objective on shares of Mirati Therapeutics in a report on Wednesday, April 12th. Zacks Investment Research raised shares of Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Wednesday, May 3rd. Finally, ValuEngine raised shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th.
Shares of Mirati Therapeutics (NASDAQ MRTX) opened at 4.35 on Tuesday. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $7.22. The stock’s market capitalization is $108.48 million. The firm’s 50-day moving average price is $3.36 and its 200 day moving average price is $4.73.
Institutional investors have recently bought and sold shares of the stock. KCG Holdings Inc. purchased a new position in Mirati Therapeutics during the first quarter worth $106,000. Trexquant Investment LP raised its position in shares of Mirati Therapeutics by 21.1% in the fourth quarter. Trexquant Investment LP now owns 26,432 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 4,599 shares during the period. Bank of New York Mellon Corp raised its position in shares of Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 11,753 shares during the period. Omega Advisors Inc. bought a new position in shares of Mirati Therapeutics during the first quarter valued at approximately $520,000. Finally, RTW Investments LP raised its position in shares of Mirati Therapeutics by 0.4% in the fourth quarter. RTW Investments LP now owns 129,697 shares of the biotechnology company’s stock valued at $616,000 after buying an additional 568 shares during the period. 64.60% of the stock is owned by institutional investors and hedge funds.
Mirati Therapeutics Company Profile
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.